Article Figures & Data
Figures
- FIG 1.
The flow chart of selecting eligible studies in the present work.
- FIG 2.
The complete occlusion rate of FD and CEV treatments at the last follow-up.
- FIG 3.
The comparison of recurrence (A) and retreatment (B) of FD and CEV treatment.
- FIG 4.
The subgroup analysis based on the aneurysm size to find the source of heterogeneity for the follow-up complete occlusion rate.
Tables
- Table 1:
The quality assessments based on Newcastle-Ottawa Scale for included cohort studies
Author Selection Comparability Outcome Year A B C D E F G H Quality Scores Chalouhi et al15 2013 * * * * * * * * 8 Zhang et al29 2016 * * * * * * * 7 Lanzino et al20 2012 * * * * * * * 7 Chalouhi et al14 2014 * * * * * * * * 8 Chalouhi et al13 2017 * * * * * * * * 8 Salem et al24 2020 * * * * * * * * 8 Durst et al17 2016 * * * * * * * 7 Yupeng Zhang et al28 2019 * * * * * * * 7 Lu et al22 2019 * * * * * * 6 Silva et al25 2019 * * * * * * * 7 Adeeb et al12 2017 * * * * * * 6 Petr et al23 2016 * * * * * * * 7 Zanaty et al27 2014 * * * * * * * 7 Di Maria et al16 2015 * * * * * * * 7 Kim et al19 2014 * * * * * * * 7 Enriquez-Marulanda et al18 2019 * * * * * * * 7 Liu et al21 2018 * * * * * * * 7 Wang et al26 2019 * * * * * * 6 Note:—Asterisk indicates that the included study meet the quality assessment criteria.
A, Representativeness of the exposed cohort.
B, Selection of the nonexposed cohort.
C, Ascertainment of exposure.
D, Demonstration that the outcome of interest was not present at the start of the study.
E, Comparability of cohorts on the basis of the design or analysis.
F, Assessment of outcome.
G, Was follow-up long enough for outcomes to occur?
H, Adequacy of follow-up of cohorts.
Variables Studies, No. FD, No. CEV, No. OR/SMD 95% CI I2 P Value Age 9 361 522 –0.23a –0.55–0.09 78% .166 Female 17 910 1076 1.02 0.79–1.32 7% .864 Hypertension 6 272 210 1.19 0.82–1.72 0% .357 Diameter of aneurysm 10 464 712 0.22a 0.03–0.41 52% .026 Periprocedural death 17 910 1076 1.81 0.73–4.48 0% .197 Periprocedural ischemia 16 848 1053 0.85 0.53–1.36 0% .505 Periprocedural hemorrhage 16 848 1053 1.51 0.80–2.8 0% .204 Procedure-related complications 17 910 1076 1.4 1.01–1.96 0% .045 Immediate occlusion 7 302 405 0.27 0.04–1.69 92% .16 mRS at discharge 6 249 263 0.43 0.15–1.23 0% .117 Follow-up occlusion 18 952 1055 2.55 1.70–3.83 68% <.001 Recurrence 5 215 310 0.24 0.12–0.46 38% <.001 Retreatment 11 670 818 0.31 0.21–0.47 33% <.001 Delayed complications 11 582 708 1.14 0.46–2.84 59% .775 mRS at follow-up 14 763 883 1.24 0.82–1.88 0% .304 ↵a Represents the SMD result.
